Middle East & Africa Immune Checkpoint Inhibitors Market Size & Outlook
Middle East & Africa immune checkpoint inhibitors market, 2018-2030 (US$M)
Related Markets
MEA immune checkpoint inhibitors market highlights
- The MEA immune checkpoint inhibitors market generated a revenue of USD 874.7 million in 2023.
- The market is expected to grow at a CAGR of 16.8% from 2024 to 2030.
- In terms of segment, pd-1 was the largest revenue generating type in 2023.
- Other Types is the most lucrative type segment registering the fastest growth during the forecast period.
- Country-wise, UAE is expected to register the highest CAGR from 2024 to 2030.
MEA data book summary
| Market revenue in 2023 | USD 874.7 million |
| Market revenue in 2030 | USD 2,591.5 million |
| Growth rate | 16.8% (CAGR from 2023 to 2030) |
| Largest segment | Pd-1 |
| Fastest growing segment | Other Types |
| Historical data covered | 2018 - 2022 |
| Base year for estimation | 2023 |
| Forecast period covered | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | PD-1, PD-L1, CTLA-4, Other Types |
| Key market players worldwide | Sanofi SA, Roche, Merck & Co Inc, Bristol-Myers Squibb Co, Eli Lilly and Co, Regeneron Pharmaceuticals Inc, AstraZeneca PLC, Shanghai Junshi Biosciences Co Ltd Class H, BeiGene Ltd ADR, GlaxoSmithKline |
Other key industry trends
- In terms of revenue, MEA region accounted for 1.8% of the global immune checkpoint inhibitors market in 2023.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 21,472.2 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Immune Checkpoint Inhibitors Market Scope
Immune Checkpoint Inhibitors Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Middle East & Africa immune checkpoint inhibitors market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to immune checkpoint inhibitors market will help companies and investors design strategic landscapes.
Pd-1 was the largest segment with a revenue share of 73.66% in 2023. Horizon Databook has segmented the Middle East & Africa immune checkpoint inhibitors market based on pd-1, pd-l1, ctla-4, other types covering the revenue growth of each sub-segment from 2018 to 2030.
- Middle East & Africa Immune Checkpoint Inhibitors Type Outlook (Revenue, USD Million, 2018-2030)
- PD-1
- PD-L1
- CTLA-4
- Other Types
- Middle East & Africa Immune Checkpoint Inhibitors Application Outlook (Revenue, USD Million, 2018-2030)
- Lung Cancer
- Breast Cancer
- Bladder Cancer
- Melanoma
- Cervical Cancer
- Hodgkin Lymphoma
- Colorectal Cancer
- Other Applications
- Middle East & Africa Immune Checkpoint Inhibitors Distribution Channel Outlook (Revenue, USD Million, 2018-2030)
- Hospital Pharmacy
- Specialty Pharmacy
- Online Pharmacy
Reasons to subscribe to Middle East & Africa immune checkpoint inhibitors market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Middle East & Africa immune checkpoint inhibitors market databook
-
Our clientele includes a mix of immune checkpoint inhibitors market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Middle East & Africa immune checkpoint inhibitors market, including forecasts for subscribers. This continent databook contains high-level insights into Middle East & Africa immune checkpoint inhibitors market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Middle East & Africa immune checkpoint inhibitors market
Middle East & Africa Immune Checkpoint Inhibitors Market Share, 2023 & 2030 (US$M)
Middle East & Africa immune checkpoint inhibitors market
Related industry reports
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
